Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/78388
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGiles, K.en
dc.contributor.authorHutchinson, A.en
dc.contributor.authorWilson, C.en
dc.contributor.authorNettelbeck, T.en
dc.date.issued2013en
dc.identifier.citationCancer Treatment Reviews, 2013; 39(3):297-304en
dc.identifier.issn0305-7372en
dc.identifier.issn1532-1967en
dc.identifier.urihttp://hdl.handle.net/2440/78388-
dc.description.abstractOBJECTIVE: The aim of this meta-analysis was to assess whether chemotherapy-related cognitive impairment is consistently observed in cancer patients and to identify the areas of cognition affected. METHODS: The meta-analysis included 13 studies and examined the effects of chemotherapy on seven different cognitive domains, across five cancer types. It was the intention of this meta-analysis to stringently exclude many studies, allowing for examination of cognition in carefully selected studies of chemotherapy recipients who do not have current mood or anxiety diagnoses (or psychiatric or substance abuse histories), without brain cancer and who have not had radiotherapy or hormone treatment. A moderator analysis examined whether patient age, treatment duration and time since treatment end significantly contributed to chemotherapy-related cognitive impairment. RESULTS: Evidence for the presence of cognitive impairment following cancer treatment was established for executive function and memory. No relationship was found between cognitive impairment and time since treatment cessation but a significant negative relationship was found for treatment duration. Age had no impact on treatment-related cognitive impairment. CONCLUSIONS: Future research must be conducted on chemotherapy-related cognitive impairment in cancer types such as lymphoma and leukaemia, which have received a moderate amount of attention and colorectal cancer, which has received little attention. This would enable us to determine the extent to which chemotherapy-related cognitive impairment is a universal phenomenon associated with the cancer experience and its treatment regardless of cancer type.en
dc.description.statementofresponsibilityKristy D. Hodgson, Amanda D. Hutchinson, Carlene J. Wilson and Ted Nettelbecken
dc.language.isoenen
dc.publisherW B Saunders Co Ltden
dc.rights© 2012 Elsevier Ltd. All rights reserved.en
dc.subjectHumans; Neoplasms; Antineoplastic Agents; Cognition; Cognition Disordersen
dc.titleA meta-analysis of the effects of chemotherapy on cognition in patients with canceren
dc.typeJournal articleen
dc.identifier.rmid0020125818en
dc.identifier.doi10.1016/j.ctrv.2012.11.001en
dc.identifier.pubid21017-
pubs.library.collectionPsychology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidHutchinson, A. [0000-0003-3983-8321]en
dc.identifier.orcidWilson, C. [0000-0002-1883-4690]en
Appears in Collections:Psychology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.